Abstract 3364
Background
RAS mutational status is an essential criterion to guide first-line treatment in metastatic colorectal cancer (mCRC). MORE-RAS was a multicenter, multicountry, observational, ambispective (retrospective + prospective) study conducted in the Middle East and North Africa (MENA) region to assess RAS testing practices and tumor characteristics in newly diagnosed patients (pts) with mCRC. Results of the retrospective analysis are presented here.
Methods
Eligible pts included adults aged ≥18 with mCRC who had already initiated first-line therapy, had at least 1 post-baseline visit for disease evaluation, and had available survival data. Pts with incomplete and unavailable data or presence of other coexisting malignancies were excluded. Data from eligible pts were retrospectively analysed 2 years back from the day of patient consent.
Results
A total of 495 pts (median age: 57 y) were enrolled; majority were male (55.6%), with adenocarcinoma histology, stage IV disease (86.8%) and left-sided tumors (79%). Primary tumor site was sigmoid (40.9%), followed by rectal (26.1%), ascending (17.2%), descending (12.1%), and transverse (3.8%) colon. RAS testing was requested in 417 (78%) pts; reasons for not prescribing included test unavailability, financial/medical decision, or other. Testing samples were mostly paraffin-embedded (91.7%) primary tumors (92.5%); sequencing was the most common test method used. RAS testing found that 33.9% of tumors harbored mutations and 66.1% carried wild-type (WT) sequences. The most common mutation was KRAS (94.1%), occurring largely in Exon2-Codon12 (70.5%). RAS testing was typically prescribed after initiation of first-line treatment, significantly more in pts with stage IV disease (p < 0.005), resulted in addition of targeted therapy (41.8% anti EGFR, 30.2% anti VEGF) in WT mCRC, and significantly impacted treatment strategy of left-sided tumors (p = 0.037).
Conclusions
RAS testing for mCRC in the MENA region was often performed after first-line treatment. The dominance of WT RAS in this region is distinct from the mutational pattern reported in Western countries.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Amgen.
Funding
Amgen.
Disclosure
M. Oukkal: Advisory / Consultancy, Speaker Bureau / Expert testimony: Amgen; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Roche; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pfizer; Speaker Bureau / Expert testimony: Bayer; Speaker Bureau / Expert testimony: Ipsen. H. Mahfouf: Advisory / Consultancy, Speaker Bureau / Expert testimony: Amgen; Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck; Advisory / Consultancy, Speaker Bureau / Expert testimony: Bayer; Advisory / Consultancy: Ipsen. A. Ouamer: Full / Part-time employment: Amgen. L. Bashir: Full / Part-time employment: Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
4732 - Progesterone Receptor Isoform Ratio Dictates Antiprogestins/Progestins Effects on Metastatic Breast Cancer Models
Presenter: Maria Abascal
Session: Poster Display session 2
Resources:
Abstract
5737 - PAM50 and CGH-array genomic characterization of HER2-Equivocal Breast Cancers defined by the 2018 ASCO/CAP recommendations.
Presenter: Carine Ngo
Session: Poster Display session 2
Resources:
Abstract
1096 - OncotypeDX® predictive nomogram for recurrence score output: a machine learning system based on quantitative immunochemistry analysis - ADAPTED01
Presenter: Fabio Marazzi
Session: Poster Display session 2
Resources:
Abstract
5426 - Geriatric parameters predict both disease-related and patient-reported outcomes in older patients with breast cancer
Presenter: Willeke van der Plas-Krijgsman
Session: Poster Display session 2
Resources:
Abstract
5865 - Patients with a 21-gene assay in South East London differ from the TAILORx trial population
Presenter: Charalampos Gousis
Session: Poster Display session 2
Resources:
Abstract
1312 - Predictive tools in adjuvant breast cancer – what is the standard of evidence supporting their utility? A literature review examining validation of Adjuvant!, Cancermath and NHS Predict
Presenter: Alice Loft
Session: Poster Display session 2
Resources:
Abstract
2445 - Oncologic outcome of invasive lobular carcinoma: Is it different from that of invasive ductal carcinoma?
Presenter: Hee Jun Choi
Session: Poster Display session 2
Resources:
Abstract
2476 - Pathologic response and survival efficacy in patients with initial nodal involvement after neoadjuvant chemotherapy in early breast cancer
Presenter: SERAFIN MORALES Murillo
Session: Poster Display session 2
Resources:
Abstract
3761 - Chemotherapy-induced amenorrhea: prognostic impact on premenopausal Egyptian patients with breast cancer
Presenter: Khaled Abdel Karim
Session: Poster Display session 2
Resources:
Abstract
4687 - Predicting the presence of breast cancer using circulating small RNA in the serum
Presenter: Yumiko Koi
Session: Poster Display session 2
Resources:
Abstract